The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis
Open accessAbstract
UNLABELLED: Primary sclerosing cholangitis (PSC) is a chronic, idiopathic, fibroinflammatory cholangiopathy. The role of the microbiota in PSC etiopathogenesis may be fundamentally important, yet remains obscure. We tested the hypothesis that germ-free (GF) mutltidrug resistance 2 knockout (mdr2(-/-) ) mice develop a distinct PSC phenotype, compared to conventionally housed (CV) mdr2(-/-) mice. Mdr2(-/-) mice (n = 12) were rederived as GF by embryo transfer, maintained in isolators, and sacrificed at 60 days in parallel with age-matched CV mdr2(-/-) mice. Serum biochemistries, gallbladder bile acids, and liver sections were examined. Histological findings were validated morphometrically, biochemically, and by immunofluorescence microscopy (IFM). Cholangiocyte senescence was assessed by p16(INK4a) in situ hybridization in liver tissue and by senescence-associated β-galactosidase staining in a culture-based model of insult-induced senescence. Serum biochemistries, including alkaline phosphatase, aspartate aminotransferase, and bilirubin, were significantly higher in GF mdr2(-/-) (P < 0.01). Primary bile acids were similar, whereas secondary bile acids were absent, in GF mdr2(-/-) mice. Fibrosis, ductular reaction, and ductopenia were significantly more severe histopathologically in GF mdr2(-/-) mice (P < 0.01) and were confirmed by hepatic morphometry, hydroxyproline assay, and IFM. Cholangiocyte senescence was significantly increased in GF mdr2(-/-) mice and abrogated in vitro by ursodeoxycholic acid (UDCA) treatment. CONCLUSIONS: GF mdr2(-/-) mice exhibit exacerbated biochemical and histological features of PSC and increased cholangiocyte senescence, a characteristic and potential mediator of progressive biliary disease. UDCA, a commensal microbial metabolite, abrogates senescence in vitro. These findings demonstrate the importance of the commensal microbiota and its metabolites in protecting against biliary injury and suggest avenues for future studies of biomarkers and therapeutic interventions in PSC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“total elimination of intestinal microbiome in germ-free mice has been shown to aggravate liver injury in mouse models of liver fibrosis and PSC.64 65”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [65]
In the citing paper
“It has become apparent that the endogenous commensal microbiota provides hepatoprotective signals and that complete absence of the gut microbiota results in increased liver injury — probably owing to an absence of TLR4-mediated activation of anti-apoptotic NF-κB signalling — and a subsequent increase in liver fibrosis, as demonstrated in several models13,75,76.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [76]
In the citing paper
“However, recent studies have demonstrated an increase in liver fibrosis in germ-free mice75,76, which seemingly contradicts the decrease of liver fibrosis seen in gut-sterilized mice.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251
Interactions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173 · cited 1×
“Although still an active area of research, the protective effects of the commensal microbiota can be considered in two broad categories: (1) production of cytoprotective metabolites (or decreased production of injurious metabolites)(40-42) and (2) facilitation of normal immunological development.(42) Fig.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 2×
“With this in mind, it is plausible that an alternative potential explanation for the increased degree of cholangiocyte senescence in GF mdr22/2 mice might be a relative immunological defect in GF mdr22/2 mice resulting in impaired clearance of senescent BECs.49,50 Senescent cell clearance has only recently been explor…”
BackgroundChemokine signaling via the CXCR2 receptor reinforces senescence
Acosta, J. C., O'Loghlen, A., Banito, A., Guijarro, M. V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, M., Brown, C., Popov, N., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.038 · Cited by 1,801 · cited 1×
“, induce senescence in neighboring cells), and initiate profibroinflammatory and protumorigenic cellular responses and outcomes.(43,45,46) Therefore, we propose that the high proportion of senescent cholangiocytes observed in GF mdr2 mice represents both a marker as well as a driver of more severe hepatobiliary diseas…”
BackgroundCellular senescence and the senescent secretory phenotype: therapeutic opportunities
Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J., & Kirkland, J. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64098 · Cited by 1,774 · cited 2×
“Senescent cell clearance has only recently been explored, but may ultimately hold therapeutic promise in PSC (even in more advanced stages of disease) and other disorders.(44) In summary, by generating the first GF variant of the mdr2 murine model of PSC, we have demonstrated that the absence of the commensal microbio…”
BackgroundEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Microbial Exposure During Early Life Has Persistent Effects on Natural Killer T Cell Function
Olszak, T., An, D., Zeissig, S., Vera, M. P., Richter, J., Franke, A., Glickman, J. N., Siebert, R., Baron, R. M., Kasper, D. L., et al. (2012) · Science · doi:10.1126/science.1219328 · Cited by 1,661
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
Kang, T.-W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., et al. (2011) · Nature · doi:10.1038/nature10599 · Cited by 1,621 · cited 2×
“With this in mind, it is plausible that an alternative potential explanation for the increased degree of cholangiocyte senescence in GF mdr22/2 mice might be a relative immunological defect in GF mdr22/2 mice resulting in impaired clearance of senescent BECs.49,50 Senescent cell clearance has only recently been explor…”
BackgroundSmit, J., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van ROON, M. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90380-9 · Cited by 1,456
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R. W., Fevery, J., Kalloo, A. N., Nagorney, D. M., Boberg, K. M., Shneider, B. L., & Gores, G. J. (2009) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,230
Yamaguchi, K., Yang, L., McCall, S. J., Huang, J., Yu, X. X., Pandey, S., Bhanot, S., Monia, B. P., Li, Y.-X., & Diehl, A. M. (2007) · Hepatology · doi:10.1002/hep.21655 · Cited by 1,067
Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases
Duboc, H., Rajca, S., Rainteau, D., Benarous, D., Maubert, M.-A., Quervain, E., Thomas, G., Barbu, V., Humbert, L., Despras, G., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302578 · Cited by 930
Clinicopathologic features of the syndrome of primary sclerosing cholangitis
Wiesner, R. H., & LaRusso, N. F. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90131-6 · Cited by 556
Self-citationProbiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity
Ukena, S. N., Singh, A., Dringenberg, U., Engelhardt, R., Seidler, U., Hansen, W., Bleich, A., Bruder, D., Franzke, A., Rogler, G., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001308 · Cited by 482 · cited 1×
“1).(25,26) Mean liver weight was similar between groups (1.”
BackgroundAbrams, G. D., Bauer, H., & Sprinz, H. (1963) · PubMed · Cited by 482
Natural history and prognostic variables in primary sclerosing cholangitis
Farrant, J. M., Hayllar, K. M., Wilkinson, M. L., Karani, J., Portmann, B. C., Westaby, D., & Williams, R. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90673-9 · Cited by 468
Fickert, P., Fuchsbichler, A., Wagner, M., Zollner, G., Kaser, A., Tilg, H., Krause, R. G. E., Lammert, F., Langner, C., Zatloukal, K., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.009 · Cited by 468 · cited 1×
“Because mdr2 mice typically develop substantial sclerosing cholangitis by this time point, we also examined GF and CV mdr2 mice at 30 days of age.(15) Serum, gallbladder bile, and liver were collected at time of sacrifice from all mice.”
BackgroundFickert, P., Zollner, G., Fuchsbichler, A., Stumptner, C., Weiglein, A. H., Lammert, F., Marschall, H., Tsybrovskyy, O., Zatloukal, K., Denk, H., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35948 · Cited by 314 · cited 1×
“However, UDCA feeding started later (2-month-old mice), when fibro-obliteration is present, induced bile infarcts and exacerbated disease phenotype.(48) Whether improved inflammation and fibrosis in UDCA-fed mice correlates with diminished senescence in this model remains to be determined.”
BackgroundThe intestinal microbiota and chronic disorders of the gut
Dupont, A. W., & DuPont, H. L. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.133 · Cited by 310
Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302 · cited 1×
“, induce senescence in neighboring cells), and initiate profibroinflammatory and protumorigenic cellular responses and outcomes.(43,45,46) Therefore, we propose that the high proportion of senescent cholangiocytes observed in GF mdr2 mice represents both a marker as well as a driver of more severe hepatobiliary diseas…”
BackgroundTabibian, J. H., Weeding, E., Jorgensen, R. A., Petz, J. L., Keach, J. C., Talwalkar, J. A., & Lindor, K. D. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12232 · Cited by 267 · cited 1×
“provided rationale for several recent pilot studies of oral antibiotics in patients with PSC, the results of which appear promising.(37) Therefore, given the previous studies suggesting a detrimental effect of the microbiota in the pathogenesis of PSC, we predicted an attenuated PSC phenotype in the absence of the com…”
ResultSelf-citationLouis, H., Laethem, J. V., Wu, W., Quertinmont, E., Degraef, C., Berg, K. V. D., Demols, A., Goldman, M., Moine, O. L., Geerts, A. E., et al. (1998) · Hepatology · doi:10.1002/hep.510280621 · Cited by 256
Banales, J. M., Sáez, E., Úriz, M., Sarvide, S., Urribarri, A. D., Splinter, P., Tietz Bogert, P. S., Bujanda, L., Prieto, J., Medina, J. F., et al. (2012) · Hepatology · doi:10.1002/hep.25691 · Cited by 250
Self-citationTabibian, J. H., O'Hara, S. P., Splinter, P. L., Trussoni, C. E., & LaRusso, N. F. (2014) · Hepatology · doi:10.1002/hep.26993 · Cited by 241
Self-citationChen, X., O’Hara, S. P., Nelson, J. B., Splinter, P. L., Small, A. J., Tietz, P. S., LIMPER, A. H., & LaRusso, N. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7447 · Cited by 231 · cited 1×
“, Toll-like receptors; TLRs) necessary to sense and respond to them.(31) Moreover, in the case of PSC, BECs accumulate bacterial endotoxin(32) and exhibit hypersensitivity to it in vitro.”
BackgroundSelf-citationCommensal microbiota is hepatoprotective and prevents liver fibrosis in mice
Mazagova, M., Wang, L., Anfora, A. T., Wissmueller, M., Lesley, S. A., Miyamoto, Y., Eckmann, L., Dhungana, S., Pathmasiri, W., Sumner, S., et al. (2015) · The FASEB Journal · doi:10.1096/fj.14-259515 · Cited by 199 · cited 1×
“However, the more severe phenotype observed in our GF animals is congruent with recent observations demonstrating more severe hepatic injury, including fibrosis, in GF C57BL/6 mice treated with the hepatotoxins, carbon tetrachloride or thioacetamide.(39) Intriguingly, in this same study, a similar severe phenotype was…”
ResultGut microbiota and probiotics in chronic liver diseases
Cesaro, C., Tiso, A., Del Prete, A., Cariello, R., Tuccillo, C., Cotticelli, G., del Vecchio Blanco, C., & Loguercio, C. (2011) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.10.015 · Cited by 182 · cited 1×
“An evolving concept of progressive tissue injury and fibrosis in chronic liver disease involves increased intestinal permeability and translocation of bacterial molecules and metabolites from the intestinal tract.(38) At a histological level, we observed typical intestinal alterations associated with the GF state, inc…”
BackgroundBangarulingam, S. Y., Björnsson, E., Enders, F., Fritcher, E. G. B., Gores, G. J., Halling, K. C., & Lindor, K. D. (2009) · Hepatology · doi:10.1002/hep.23277 · Cited by 172 · cited 1×
“P rimary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease characterized by biliary inflammation and periductal fibrosis,(1,2) a median liver transplantation (LT)-free survival of 12 years,(3) and a predisposition to hepatobiliary carcinogenesis.(4,5) Despite ongoing research over several decades, s…”
BackgroundNieuwkerk, C. V., Elferink, R. P. J. O., Groen, A. K., Ottenhoff, R., Tytgat, G. N. J., Dingemans, K. P., Weerman, M. V. D. B., & Offerhaus, G. J. A. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8698195 · Cited by 170 · cited 1×
“Intriguingly, previous reports have demonstrated that UDCA feeding in the MDR2 mouse, when started immediately after weaning, improved fibrosis and inflammation.(47) However, UDCA feeding started later (2-month-old mice), when fibro-obliteration is present, induced bile infarcts and exacerbated disease phenotype.”
Weismüller, T. J., Wedemeyer, J., Kubicka, S., Strassburg, C. P., & Manns, M. P. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.020 · Cited by 163 · cited 2×
“In addition to and extending these associations is a growing number of studies suggesting that the intestinal microbiota plays an important pathophysiological role in PSC, hence providing the basis of the “leaky gut” hypothesis.(1,2) The focus of these studies, though, has been on the deleterious effects of microbial…”
BackgroundHeuman, D. M., Hylemon, P. B., & Vlahcevic, Z. R. (1989) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38276-6 · Cited by 161
Sasatomi, K., Noguchi, K., Sakisaka, S., Sata, M., & Tanikawa, K. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80058-5 · Cited by 146
Planell-Saguer, M. D., Rodicio, M. C., & Mourelatos, Z. (2010) · Nature Protocols · doi:10.1038/nprot.2010.62 · Cited by 145 · cited 1×
“Expression of p16 messenger RNA (mRNA), a wellestablished marker of cellular senescence, was assessed by fluorescence in situ hybridization (FISH), as previously described.(18,23) Briefly, liver section slides were deparaffinized, rehydrated, and boiled in sodium citrate buffer.”
MethodCellular senescence, ageing and disease
Burton, D. G. A. (2008) · AGE · doi:10.1007/s11357-008-9075-y · Cited by 140 · cited 2×
“These two findings, which may be inter-related, are relevant given that senescent cells can transition to a potentially pathological state referred to as a senescenceassociated secretory phenotype (SASP).(18,43,44) SASP cells, in turn, can alter their microenvironment, reinforce the senescent phenotype (e.”
BackgroundBile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers
Olsson, R., Björnsson, E., Bäckman, L., Friman, S., Höckerstedt, K., Kaijser, B., & Olausson, M. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80316-4 · Cited by 133
Biliary tract disease in rats with experimental small bowel bacterial overgrowth
Lichtman, S. N., Keku, J., Clark, R. L., Schwab, J. H., & Sartor, R. B. (1991) · Hepatology · doi:10.1002/hep.1840130425 · Cited by 130
Pohl, J., Ring, A., Stremmel, W., & Stiehl, A. (2006) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200601000-00012 · Cited by 111
Ngu, J. H., Gearry, R. B., Wright, A. J., & Stedman, C. A. M. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.027 · Cited by 107 · cited 1×
“Indeed, IBD (most often ulcerative colitis), a chronic disorder characterized by enteric microbial dysbiosis,(11,12) is found in approximately 75% of PSC patients.(13,14) In addition to and extending these associations is a growing number of studies suggesting that the intestinal microbiota plays an important pathophy…”
BackgroundHiramatsu, K., Harada, K., Tsuneyama, K., Sasaki, M., Fujita, S., Hashimoto, T., Kaneko, S., Kobayashi, K., & Nakanuma, Y. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80153-1 · Cited by 97
Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis
Tabibian, J. H., Talwalkar, J. A., & Lindor, K. D. (2013) · BioMed Research International · doi:10.1155/2013/389537 · Cited by 91
Self-citationMueller, T., Beutler, C., Picó, A. H., Shibolet, O., Pratt, D. S., Pascher, A., Neuhaus, P., Wiedenmann, B. J., Berg, T., & Podolsky, D. K. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02635.x · Cited by 85 · cited 1×
“Moreover, in the case of PSC, BECs accumulate bacterial endotoxin(32) and exhibit hypersensitivity to it in vitro.(33) These and other supporting data(34,35) (recently reviewed by us elsewhere(36)) have Fig.”
BackgroundPrimary Sclerosing Cholangitis: Epidemiology, Natural History, and Prognosis
Levy, C., & Lindor, K. D. (2006) · Seminars in Liver Disease · doi:10.1055/s-2006-933560 · Cited by 84 · cited 1×
“PSC is a clinically heterogeneous disease with genetic, immunological, environmental, and other potential etiopathogenic components.(1,2,10) It exhibits remarkable epidemiologic and pathobiological associations with inflammatory bowel disease (IBD).”
BackgroundOutcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries
Brandsaeter, B. J., Friman, S., Broomé, U., Isoniemi, H., Olausson, M., Bäckman, L., Hansen, B., Schrumpf, E., Oksanen, A., Ericzon, B. ‐., et al. (2003) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520310006009 · Cited by 65
Primary sclerosing cholangitis: a review and update on therapeutic developments
Tabibian, J. H., & Lindor, K. D. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.12.80 · Cited by 61 · cited 2×
“In addition to and extending these associations is a growing number of studies suggesting that the intestinal microbiota plays an important pathophysiological role in PSC, hence providing the basis of the “leaky gut” hypothesis.(1,2) The focus of these studies, though, has been on the deleterious effects of microbial…”
BackgroundSelf-citationSmall duct cholangitis induced byn-formyll-methioninel-leucinel-tyrosine in rats
Yamada, S., Ishii, M., Liang, L., Yamamoto, T., & Toyota, T. (1994) · Journal of Gastroenterology · doi:10.1007/bf02365447 · Cited by 59
Effect of Antioxidant Treatment on Fibrogenesis in Rats with Carbon Tetrachloride-Induced Cirrhosis
Bona, S., Filippin, L. I., Naso, F. C. D., de David, C., Valiatti, B. B., Schaun, M. I., Xavier, R. M., & Marroni, N. P. (2012) · ISRN Gastroenterology · doi:10.5402/2012/762920 · Cited by 43
Ali, J. M., Bonomo, L. D., Brais, R. J., Griffiths, W. J., Lomas, D. J., Huguet, E., Praseedom, R., Jamieson, N. V., & Jah, A. (2011) · Transplantation · doi:10.1097/tp.0b013e31821aba57 · Cited by 38
Tabibian, J. H., Macura, S. I., O’Hara, S. P., Fidler, J. L., Glockner, J. F., Takahashi, N., Lowe, V. J., Kemp, B. J., Mishra, P. K., Tietz, P. S., et al. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.52 · Cited by 33
Self-citationChallenges of Cholangiocarcinoma Detection in Patients with Primary Sclerosing Cholangitis
Tabibian, J. H., & Lindor, K. D. (2012) · Journal of Analytical Oncology · doi:10.6000/1927-7229.2012.01.01.7 · Cited by 27 · cited 1×
“P rimary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease characterized by biliary inflammation and periductal fibrosis,(1,2) a median liver transplantation (LT)-free survival of 12 years,(3) and a predisposition to hepatobiliary carcinogenesis.(4,5) Despite ongoing research over several decades, s…”
BackgroundSelf-citation
Flagged first, then by citations
1 of the 50 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Gut-liver axis: Pathophysiological concepts and clinical implications
Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.017 · Cited by 843
The gut microbiome and liver cancer: mechanisms and clinical translation
Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634
Bernardi, M., Moreau, R., Angeli, P., Schnabl, B., & Arroyo, V. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.004 · Cited by 645
Gut microbiome and liver diseases
Tilg, H., Cani, P. D., & Mayer, E. A. (2016) · Gut · doi:10.1136/gutjnl-2016-312729 · Cited by 525
Interactions between gut bacteria and bile in health and disease
Long, S. L., Gahan, C. G. M., & Joyce, S. A. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.06.002 · Cited by 495
Metadata
- Authors
- Tabibian, J. H., O'Hara, S. P., Trussoni, C. E., Tietz, P. S., Splinter, P. L., Mounajjed, T., Hagey, L. R., & LaRusso, N. F.
- Affiliations
- Mayo Clinic (US)
- Division of Gastroenterology and Hepatology,Mayo Clinic,Rochester,MN
- University of California San Diego (US)
- Corresponding author
- LaRusso, Nicholas F.
- Venue
- Hepatology
- Published
- 2015-08-10
- Volume
- 63
- Issue
- 1
- Pages
- 185-196
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- PMC
- PMC4670294
- OpenAlex
- W1945590693
- Cited by
- 223
- References
- 50
- Citations by year
- 2026: 14 · 2025: 7 · 2024: 17 · 2023: 18 · 2022: 17 · 2021: 24 · 2020: 20 · 2019: 25 · 2018: 27 · 2017: 28 · 2016: 19 · 2015: 5
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Mayo Clinic (P30 DK084567)
- Mayo Foundation for Medical Education and Research
- PSC Partners Seeking a Cure
- National Institutes of Health
- University of California, San Diego
- Center for Cell Signaling in Gastroenterology, Mayo Clinic (P30 DK084567)
- National Institute of Allergy and Infectious Diseases (R01AI089713, AI089713)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57993, P30DK084567, R01DK057993)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- primary sclerosing cholangitis, gut microbiota, germ-free mice, Mdr2 knockout mice, bile acid metabolism, secondary bile acids, ursodeoxycholic acid, liver fibrosis, ductopenia, biliary injury
- MeSH terms
- Gastrointestinal Microbiome, Animals, Disease Models, Animal, Female, Male, Cholangitis, Sclerosing, Mice, Knockout, Disease Progression, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
